fbpx
2021 Myopia Report available

Canadian ECP Myopia Survey Now Available

The 2021 Canadian ECPs survey on the usage of and attitudes towards myopia control therapies in now available. Click Here to start the survey.

Eligible participants can win one of five $100 gift certificates for completing the online survey.

Results of the myopia survey will help organizations with competitive positioning, identify required adjustments in priorities and determining opportunities to better serve the needs of clients in this important new category.

The final report of the 2021 study will reveal the changes in the market during the past 2 years and thus point to emerging trends in the market.

Organizations wishing to purchase the study may reserve their intention to do so in advance and receive an early-bird discount or include one additional complimentary question in the study questionnaire.

For more information on the study methodology, report format and pricing, please contact:
David Pietrobon (dpietrobon@vuepoint.ca)   Phone:   226.780.6871 x 5111
Bill Scott (Bscott@jobson.com)    Phone:   646.831.8873

Featured Posts

Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read More
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read More
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read More
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more